Abiopharma

🔍 Schuetz Thomas J. (Director)

Company: Compass Therapeutics, Inc. (CMPX)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 250,000 shares of Common Stock at $5.17 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,686,800.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 2,000,000 shares of Stock Option (Right to Buy) at $5.17 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 2,000,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.
• F2: 250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
• F3: The options vest over 48 substantially equal monthly installments starting February 2, 2026.